iSCB Team 2020
iSCB Team 2020

Xavier Morelli

Responsable d'équipe Directeur de Recherche CNRS (DR2)
May 2020 ACS chemical biology

Fr-PPIChem: An Academic Compound Library Dedicated to Protein-Protein Interactions.

Bosc N, Muller C, Hoffer L, Lagorce D, Bourg S, Derviaux C, Gourdel ME, Rain JC, Miller TW, Villoutreix BO, Miteva MA, Bonnet P, Morelli X, Sperandio O, Roche P

Oct 2020 Molecular oncology

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.

Ariey-Bonnet J, Carrasco K, Le Grand M, Hoffer L, Betzi S, Feracci M, Tsvetkov P, Devred F, Collette Y, Morelli X, Ballester P, Pasquier E

Apr 2019 Journal of chemical information and modeling

CovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy.

Hoffer L, Saez-Ayala M, Horvath D, Varnek A, Morelli X, Roche P

May 2023 Nature communications

From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia.

Saez-Ayala M, Hoffer L, Abel S, Ben Yaala K, Sicard B, Andrieu GP, Latiri M, Davison EK, Ciufolini MA, Brémond P, Rebuffet E, Roche P, Derviaux C, Voisset E, Montersino C, Castellano R, Collette Y, Asnafi V, Betzi S, Dubreuil P, Combes S, Morelli X

Mar 2023 Journal of medicinal chemistry

Discovery of a PDZ Domain Inhibitor Targeting the Syndecan/Syntenin Protein-Protein Interaction: A Semi-Automated « Hit Identification-to-Optimization » Approach.

Hoffer L, Garcia M, Leblanc R, Feracci M, Betzi S, Ben Yaala K, Daulat AM, Zimmermann P, Roche P, Barral K, Morelli X

Apr 2022 ACS chemical biology

Discovery of Small-Molecule Inhibitors of the PTK7/β-Catenin Interaction Targeting the Wnt Signaling Pathway in Colorectal Cancer.

Ganier L, Betzi S, Derviaux C, Roche P, Dessaux C, Muller C, Hoffer L, Morelli X, Borg JP

Mar 2022 Journal of medicinal chemistry

CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.

Carrasco K, Montersino C, Derviaux C, Saez-Ayala M, Hoffer L, Restouin A, Castellano R, Casassa J, Roche P, Pasquier E, Combes S, Morelli X, Collette Y, Betzi S

Aug 2021 mBio

Inhibiting Type VI Secretion System Activity with a Biomimetic Peptide Designed To Target the Baseplate Wedge Complex.

Cherrak Y, Filella-Merce I, Schmidt V, Byrne D, Sgoluppi V, Chaiaheloudjou R, Betzi S, Morelli X, Nilges M, Pellarin R, Durand E

Jun 2021 European journal of medicinal chemistry

Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread.

Garcia M, Hoffer L, Leblanc R, Benmansour F, Feracci M, Derviaux C, Egea-Jimenez AL, Roche P, Zimmermann P, Morelli X, Barral K

Feb 2021 Biology of the cell

The NANOTUMOR consortium – Towards the Tumor Cell Atlas.

Colin F, Schauer K, Hamiche A, Martineau P, Borg JP, Bednar J, Bertolin G, Camoin L, Collette Y, Dimitrov S, Fournier I, Hyenne V, Mendoza-Parra MA, Morelli X, Rondé P, Sumara I, Tramier M, Schultz P, Goetz JG

Dec 2020 Journal of extracellular vesicles

Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo.

Leblanc R, Kashyap R, Barral K, Egea-Jimenez AL, Kovalskyy D, Feracci M, Garcia M, Derviaux C, Betzi S, Ghossoub R, Platonov M, Roche P, Morelli X, Hoffer L, Zimmermann P

Jan 2019 European journal of medicinal chemistry

Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors.

Hernandez J, Hoffer L, Coutard B, Querat G, Roche P, Morelli X, Decroly E, Barral K

Sep 2018 Molecular informatics

Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches.

Hoffer L, Muller C, Roche P, Morelli X